Viridian Therapeutics' stock jumps after Phase III trial met all endpoints - Yahoo Finance
Viridian Therapeutics' veligrotug met all primary and secondary endpoints in Phase III THRIVE trial for active thyroid eye disease (TED), showing significant improvements in signs and symptoms. The treatment group saw a 70% proptosis responder rate and a 2.9mm mean reduction in proptosis, compared to 5% and 0.5mm in the placebo group. Veligrotug was generally well-tolerated with mild adverse events and no serious treatment-related AEs. The company's stock price rose by 32% following the trial results.
Related Clinical Trials
Highlighted Terms
Related News
Viridian Therapeutics' veligrotug met all primary and secondary endpoints in Phase III THRIVE trial for active thyroid eye disease (TED), showing significant improvements in signs and symptoms. The treatment group saw a 70% proptosis responder rate and a 2.9mm mean reduction in proptosis, compared to 5% and 0.5mm in the placebo group. Veligrotug was generally well-tolerated with mild adverse events and no serious treatment-related AEs. The company's stock price rose by 32% following the trial results.
Viridian Therapeutics' veligrotug met all primary and secondary endpoints in Phase III THRIVE trial for thyroid eye disease (TED), showing significant improvements in signs and symptoms. The treatment group had a 70% proptosis responder rate and 54% complete resolution of diplopia, compared to 5% and 12% in the placebo group, respectively. Veligrotug was generally well-tolerated, with no treatment-related serious adverse events. The company's stock price rose by 32% following the announcement.